United Therapeutics Corporation's revenue has grown 14% a year over three years, and grown 15% a year over five, with earnings per share compounding at 17%. Revenue growth, 3-year annual rate: +14% (Drug Manufacturers - Specialty & Generic median +12%). Revenue growth, 5-year rate: +15%, growth has slowed since the five-year average. Earnings per share, 3-year rate: +17%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 18, FY2008 to FY2025, as filed.

UTHRUnited Therapeutics Corporation

Healthcare

$587.51+36% 1Y

$587.51

$415.3452 weeks$596.76

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin narrowing (−2.6 points).

1 to watch, 2 neutral

Revenue trend+2% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +15% a year.

Earnings trend+9% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction−2.6 points operating

Trailing-twelve-month operating margin, 44.4% now against 47.1% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbetter than 78% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is UTHR growing?

United Therapeutics Corporation's revenue has grown 14% a year over three years, and grown 15% a year over five, with earnings per share compounding at 17%.

+14%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +12% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +15%
Revenue growth, 5-year rate · +14% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: +17%
Earnings per share, 3-year rate · revenue +14% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 18
Years of annual history on file · FY2008 to FY2025, as filed